Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Wave Life Sciences Crashed Today

By Brian Orelli, PhD - Mar 30, 2021 at 2:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No one ever said drug development was easy.

What happened

Shares of Wave Life Sciences (WVE -0.79%) are down 29% at 1:29 p.m. EDT after the company announced that WVE-120102 and WVE-120101, two of its drugs to treat Huntington's disease, failed to show an effect in early stage clinical trials.

So what

Huntington's disease is caused by different mutations in the huntingtin protein. WVE-120101 and WVE-120102 are designed to reduce the expression of mutant huntingtin protein (mHTT) for patients with the SNP1 and SNP2 mutations, respectively.

The drugs appear to be working, but unfortunately the reduction on mHTT wasn't clinically meaningful. Results from the clinical trial testing WVE-120102 showed the highest dose of the drug reduced mHTT by 9.9% in the cerebrospinal fluid compared to a 0.8% decrease for placebo. In a separate clinical trial of WVE-120101, which wasn't as far along, the highest dose reduced mHTT by 11.6% compared to 10% for placebo.

Considering WVE-120101 and WVE-120102 use the same technology, Wave Life Sciences decided to stop clinical development of both drugs.

Doctor sitting at a desk talking to a patient

Image source: Getty Images.

Now what

Fortunately Wave Life Sciences still has one more shot on goal for Huntington's disease. WVE-003 treats patients with the SNP3 mutation, which affects 40% of patients with Huntington's disease. Importantly, the drug uses an improved backbone chemistry, which Wave Life Sciences believes will last longer in the body. The company plans to begin treating patients with WVE-003 later this year.

Beyond Huntington's disease, Wave Life Sciences also has two other drugs ready to enter the clinic this year: WVE-004 for amyotrophic lateral sclerosis and frontotemporal dementia and WVE-N531 for Duchenne muscular dystrophy.

While losing its two lead programs is devastating, Wave has enough cash to get it through the second quarter of 2023. That should be enough time to generate additional data to prove that its improved backbone chemistry works, which would allow the company to raise additional capital at a higher valuation.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Wave Life Sciences Ltd. Stock Quote
Wave Life Sciences Ltd.
$1.26 (-0.79%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.